Bile Duct Cancer Treatment–for health professionals (PDQ®)
SECTIONS
- General Information About Bile Duct Cancer
- Cellular Classification of Bile Duct Cancer
- Stage Information for Bile Duct Cancer
- Localized Bile Duct Cancer
- Unresectable, Recurrent, or Metastatic Bile Duct Cancer
- Changes to This Summary (12/09/2015)
- About This PDQ Summary
- View All Sections
Changes to This Summary (12/09/2015)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about a phase II Southwest Oncology Group (SWOG) cooperative trial (S0809) that evaluated adjuvant capecitabine and gemcitabine followed by chemoradiation for patients with resected extrahepatic cholangiocarcinoma and gallbladder cancer. Also added statistical data to support findings of the trial (cited Ben-Josef et al. as reference 5 and level of evidence 3iiiDiv).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario